BerGenBio $BGBIO upgraded target price to 86 NOK from ArcticSec
Quote:
"Bemcentinib has shown effect against SARS-CoV-2 (coronavirus) in animal models and has been selected as the first of six drugs to be fast-tracked in the new UK initiative (ACCORD) to enter a phase 2 study directly.
Although there are many uncertainties around valuing this opportunity, we estimate the new indication adds NOK 21/share, with a new TP of NOK 86.
Read-out of the phase 2 study is expected in approx. 6 weeks. Developments will be followed closely."
Source:
https://www.research-tree.com/companies/norway/biotechnology/bergenbio-asa/research/arctic-securities/unique-covid-19-possibility/61_6f4403cf-8701-4c9d-bd71-7ddcf7d508a0
"Bemcentinib has shown effect against SARS-CoV-2 (coronavirus) in animal models and has been selected as the first of six drugs to be fast-tracked in the new UK initiative (ACCORD) to enter a phase 2 study directly.
Although there are many uncertainties around valuing this opportunity, we estimate the new indication adds NOK 21/share, with a new TP of NOK 86.
Read-out of the phase 2 study is expected in approx. 6 weeks. Developments will be followed closely."
Source:
https://www.research-tree.com/companies/norway/biotechnology/bergenbio-asa/research/arctic-securities/unique-covid-19-possibility/61_6f4403cf-8701-4c9d-bd71-7ddcf7d508a0
